A Study to Test the Effect of Different Doses of BI 685509 on Kidney Function in People With Diabetic Kidney Disease

A phase 2 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 243 participants.

Also called NCT04750577

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; quadruple masking; primary purpose treatment
Phase
Phase 2
Enrolled
  • 243 participants (enrolled count) (from the registry)
Sponsor
Registry
  • NCT NCT04750577
  • EudraCT 2020-002929-28
Started
(actual) (from the registry)
Primary completion
(actual) (from the registry)
Completion
(actual) (from the registry)
Results first posted
(from the registry)
Countries
United States, Argentina, Australia, Canada, China, Denmark, Hong Kong SAR China, Japan, Malaysia, Mexico, Netherlands, New Zealand, Poland, Portugal, Spain, United Kingdom (from the registry)
Registry status
  • Completed (from the registry)

Technical summary

Registry record NCT04750577. Randomized; quadruple masking; primary purpose treatment. Start 2021-04-27 (actual); primary completion 2022-11-30 (actual). Results posted on 2024-07-23.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
A Study to Test the Effect of Different Doses of BI 685509 on Kidney Function in People With Diabetic Kidney Disease
Condition
Diabetic Nephropathies
Intervention (Drug)
Placebo matching BI 685509
Intervention (Drug)
BI 685509
Lead sponsor
Boehringer Ingelheim (class: industry)

Record details

Record id
cardio:ct-nct04750577
Content hash
ce45ccd0c6d1373541cb5e2ec533ed99d3428c1eb65777449b88efa50439c444